These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 7476901

  • 1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
    Qin ZH, Zhou LW, Zhang SP, Wang Y, Weiss B.
    Mol Pharmacol; 1995 Oct; 48(4):730-7. PubMed ID: 7476901
    [Abstract] [Full Text] [Related]

  • 2. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
    Zhou LW, Zhang SP, Qin ZH, Weiss B.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
    [Abstract] [Full Text] [Related]

  • 3. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhang SP, Zhou LW, Weiss B.
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1462-70. PubMed ID: 7996459
    [Abstract] [Full Text] [Related]

  • 4. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G, Zhou LW, Morabito M, Zhang SP, Weiss B.
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [Abstract] [Full Text] [Related]

  • 5. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT, White FJ.
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [Abstract] [Full Text] [Related]

  • 6. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS, Joyce JN.
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [Abstract] [Full Text] [Related]

  • 7. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat.
    Rajakumar N, Laurier L, Niznik HB, Stoessl AJ.
    Synapse; 1997 Jul; 26(3):199-208. PubMed ID: 9183809
    [Abstract] [Full Text] [Related]

  • 8. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhou LW, Zhang SP, Weiss B.
    Neurochem Int; 1996 Dec; 29(6):583-95. PubMed ID: 9113126
    [Abstract] [Full Text] [Related]

  • 9. Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases D2 dopamine receptor mRNA and proenkephalin mRNA and decreases D1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum.
    Chen JF, Aloyo VJ, Qin ZH, Weiss B.
    Neurochem Int; 1994 Oct; 25(4):355-66. PubMed ID: 7820070
    [Abstract] [Full Text] [Related]

  • 10. Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine.
    Silvia CP, King GR, Lee TH, Xue ZY, Caron MG, Ellinwood EH.
    Mol Pharmacol; 1994 Jul; 46(1):51-7. PubMed ID: 8058056
    [Abstract] [Full Text] [Related]

  • 11. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM, Bruno JP.
    Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
    [Abstract] [Full Text] [Related]

  • 12. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
    DeBoer P, Abercrombie ED.
    J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
    [Abstract] [Full Text] [Related]

  • 13. Diurnal rhythms in quinpirole-induced locomotor behaviors and striatal D2/D3 receptor levels in mice.
    Akhisaroglu M, Kurtuncu M, Manev H, Uz T.
    Pharmacol Biochem Behav; 2005 Mar; 80(3):371-7. PubMed ID: 15740778
    [Abstract] [Full Text] [Related]

  • 14. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum.
    Centonze D, Gubellini P, Usiello A, Rossi S, Tscherter A, Bracci E, Erbs E, Tognazzi N, Bernardi G, Pisani A, Calabresi P, Borrelli E.
    Neuroscience; 2004 Mar; 129(1):157-66. PubMed ID: 15489038
    [Abstract] [Full Text] [Related]

  • 15. The role of dopamine D2 receptor in the behavioral effects of imipramine--study with the use of antisense oligonucleotides.
    Dziedzicka-Wasylewska M, Kolasiewicz W, Rogóz Z, Margas W, Maj J.
    J Physiol Pharmacol; 2000 Sep; 51(3):401-9. PubMed ID: 11016860
    [Abstract] [Full Text] [Related]

  • 16. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
    Burger LY, Martin-Iverson MT.
    Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of fluphenazine-N-mustard, on calmodulin activity and on D1 and D2 dopaminergic responses.
    Winkler JD, Thermos K, Weiss B.
    Psychopharmacology (Berl); 1987 Jan; 92(3):285-91. PubMed ID: 2957717
    [Abstract] [Full Text] [Related]

  • 18. Tolerance to the cataleptic effect that follows repeated nitric oxide synthase inhibition may be related to functional enzymatic recovery.
    Del-Bel EA, Guimarães FS, Joca SR, Echeverry MB, Ferreira FR.
    J Psychopharmacol; 2010 Mar; 24(3):397-405. PubMed ID: 18838497
    [Abstract] [Full Text] [Related]

  • 19. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates.
    Zhang M, Creese I.
    Neurosci Lett; 1993 Oct 29; 161(2):223-6. PubMed ID: 7903803
    [Abstract] [Full Text] [Related]

  • 20. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec 29; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.